Sherk, you've been a voice of reason and insight here for a long time, so I felt compelled to comment. Many thanks. I've been long ALNY since before the Novartis deal in 2006 when the major competition was Sirna. Thought it was going to be easy before the RSV failure and then realized this was going to take more staying power. Takeda and Roche coming and going. ssRNAi. Regulus. The Tekmira lawsuit. $5/share range in 2011. Sanofi. Generations of GalNac. It's tiring just thinking about the history!